Additional value of a high sensitive thyroglobulin assay in the follow‐up of patients with differentiated thyroid carcinoma

Summary Objective Thyroglobulin (Tg) is an excellent tumour marker, as detectable or increasing Tg levels are highly indicative of persistent or recurrent differentiated thyroid carcinoma (DTC). The clinical value of a highly sensitive (hs)‐Tg assay in patients with DTC has not yet been established....

Full description

Saved in:
Bibliographic Details
Published inClinical endocrinology (Oxford) Vol. 86; no. 3; pp. 419 - 424
Main Authors Groen, Andries H., Klein Hesselink, Mariëlle S., Plukker, John T.M., Sluiter, Wim J., Horst‐Schrivers, Anouk N.A., Brouwers, Adrienne H., Lentjes, Eef G.W.M., Muller Kobold, Anneke C., Links, Thera P.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.03.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Objective Thyroglobulin (Tg) is an excellent tumour marker, as detectable or increasing Tg levels are highly indicative of persistent or recurrent differentiated thyroid carcinoma (DTC). The clinical value of a highly sensitive (hs)‐Tg assay in patients with DTC has not yet been established. The aim of this study was to investigate the additional value of unstimulated hs‐Tg measurements (Tg‐on) compared to stimulated IRMA‐Tg measurements (Tg‐off) in the follow‐up of patients with DTC. Design, patients, measurements We retrospectively studied patients treated for DTC between 2006 and 2013 and compared hs‐Tg and IRMA‐Tg measurements. The study group consisted of 99 DTC patients in remission; Tg‐on was measured 3 months after remnant ablation and Tg‐off 6 months after ablation. Results In the study group, 44 patients showed a hs‐Tg‐on <0·15 μg/l (functional sensitivity); of these, 43 had an IRMA‐Tg‐off measurement <1·0 μg/l, resulting in a negative predictive value of 97·7% and a positive predictive value of 56·4%. Conclusions The hs‐Tg‐on measurement is able to predict patients with an IRMA‐Tg‐off <1·0 μg/l, and therefore decreases the need for Tg stimulation after ablation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0300-0664
1365-2265
DOI:10.1111/cen.13180